Novartis AGFRA:NOT0 83 Net Current Asset Value is €-3.55 as of Mar. 2026. GuruFocus rates FRA:NOT0 with a GF Score™ of 83/100 and a GF Value™ of €15.09 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 613 Drug Manufacturers companies, Novartis AG ranks worse than 163131.97% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Novartis AG's net current asset value per share for the quarter that ended in Mar. 2026 was €-3.55.
The historical rank and industry rank for Novartis AG's Net Current Asset Value or its related term are showing as below:
FRA:NOT0's Price-to-Net-Current-Asset-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.63 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Novartis AG (FRA:NOT0) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Novartis AG Net Current Asset Value Related Terms
Novartis AG Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Novartis AG's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NOT0 vs LLY, JNJ, ABBV: Net Current Asset Value Comparison
For the Drug Manufacturers - General subindustry, Novartis AG's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis AG Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Novartis AG's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €-3.55 mean?
Novartis AG (FRA:NOT0) has a Net Current Asset Value of €-3.55 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Novartis AG and its competitors. According to the industry distribution chart, Novartis AG ranks #999999 out of 613 companies in the Drug Manufacturers industry.
Is Novartis AG's Net Current Asset Value too high?
Novartis AG's current Net Current Asset Value is €-3.55. Based on the distribution chart, Novartis AG ranks #999999 out of 613 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Novartis AG has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Net Current Asset Value compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novartis AG ranks #999999 out of 613 companies for Net Current Asset Value. This places Novartis AG in the lower half of its industry. The industry median Net Current Asset Value is 5.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.63, based on 613 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Novartis AG and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis AG's current Net Current Asset Value is €-3.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (FRA:NOT0) is currently considered Modestly Overvalued. The stock's GF Value™ is €15.09, compared to a current price of €18.20 — trading 20.6% above its estimated fair value. The current Net Current Asset Value is €-3.55. Novartis AG's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Novartis AG (FRA:NOT0), the current Net Current Asset Value is €-3.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis AG (FRA:NOT0) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued.
The current stock price of €18.20 is trading 20.6% above its estimated GF Value™ of €15.09.
GuruFocus considers Novartis AG to be Modestly Overvalued.
Key valuation signals for FRA:NOT0:
Net Current Asset Value: €-3.55
GF Value™: €15.09 vs. price of €18.20 (20.6% above fair value)
No single metric tells the full story. See the FRA:NOT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
83GF Score
Get the complete analysis for FRA:NOT0
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NOT0 has been successfully added to your 
